Buy the Dip, but Avoid IT, Back Pharma & Power, Says Rudramurthy BV
Companies Mentioned
Why It Matters
The call highlights a tactical shift toward defensive, earnings‑driven sectors as Indian markets correct, offering investors clearer entry points and risk‑managed trades amid lingering macro volatility.
Key Takeaways
- •Nifty entry zone: 23,700‑23,800 points
- •Avoid IT sector; earnings weakness persists
- •Pharma, power, aluminium show relative strength
- •Short Persistent Systems; target 4,600, stop 5,050
- •Long Glenmark Pharma; targets 2,550 and 2,800
Pulse Analysis
The Indian equity rally that vaulted the Nifty from 22,200 to 24,600 has given way to a sharp correction, prompting market participants to reassess risk. Rudramurthy BV points to three macro‑level signals—Brent crude consistently above $100 a barrel, the rupee trading beyond the 94‑per‑dollar threshold, and an elevated VIX—as cautionary flags. By waiting for the Nifty to slip into the 23,700‑23,800 band and Bank Nifty to hover around 55,000, investors can align entries with technical support while the upcoming monthly expiry adds liquidity.
Sector rotation is central to the current thesis. Pharma stocks have broken out and are now consolidating, suggesting accumulation by smart money. Power and energy firms continue to ride demand‑driven momentum, while select metal names, especially aluminium producers, are outperforming the broader index. These areas combine solid earnings visibility with defensive characteristics, making them attractive amid global uncertainty. Conversely, the IT sector remains in a downtrend, with weak earnings confirming its vulnerability; attempting to catch a dip here could expose investors to further losses.
Rudramurthy backs his outlook with concrete trade ideas. He recommends shorting Persistent Systems futures, targeting 4,600 with a stop at 5,050, reflecting the stock’s earnings weakness. On the upside, Glenmark Pharma is positioned as a bottom‑forming play, with near‑term and longer‑term targets of 2,550 and 2,800 respectively, and a protective stop at 2,200. These calls illustrate a disciplined approach: selective sector exposure, clear price objectives, and tight risk controls, guiding investors through the current market turbulence.
Buy the dip, but avoid IT, back pharma & power, says Rudramurthy BV
Comments
Want to join the conversation?
Loading comments...